Irene Casanova-Salas

Irene Casanova-Salas

Auto-generated profile, based on publicly available information

Irene Casanova-Salas

Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Urology
Verified
Journal Article
Closed access
ICIrene Casanova-Salas
Irene Casanova-Salas
JRJosé Rubio-Briones
José Rubio-Briones
ACAna Calatrava
Ana Calatrava
Caterina MancarellaCaterina Mancarella
Caterina Mancarella
EMEsther Masiá
Esther Masiá
JOSE ANTONIO LOPEZ-GUERREROJOSE ANTONIO LOPEZ-GUERRERO
JOSE ANTONIO LOPEZ-GUERRERO
MiRNAs are noncoding RNAs that negatively regulate target mRNA gene expression. Aberrant miRNA expression is associated with prostate cancer pathogenesis. We identified miRNAs as potential biomarkers for prostate cancer diagnosis and prognosis. Total RNA was obtained from 10 normal prostate and 50 prostate cancer samples, and analyzed using the GeneChip® miRNA 2.0 Array. At a median followup of 92 months (range 2 to 189) an independent cohort of 273 paraffin embedded prostate cancer samples was used for validation by quantitative reverse transcriptase-polymerase chain reaction. Another 92 urine samples from patients undergoing prostate biopsy were evaluated for these miRNAs. miR-182 and 187, the miRNAs most differentially expressed between normal and tumor tissue, were selected for further validation. miR-187 inversely correlated with cT (p = 0.125) and pT (p = 0.0002) stages, Gleason score (p = 0.003) and TMPRSS2-ERG status (p = 0.003). The log rank test showed associations of miR-182 with biochemical (p = 0.026) and clinical (p = 0.043) progression-free survival, as also noted on multivariate analysis. A significant independent improvement in the definition of risk of progression was achieved by combining miR-182 expression with Gleason score (p <0.0001). miR-187 detection in urine provided an independent predictive value for positive biopsy. A prediction model including serum prostate specific antigen, urine PCA3 and miR-187 provided 88.6% sensitivity and 50% specificity (AUC 0.711, p = 0.001). Results show that miR-182 and 187 are promising biomarkers for prostate cancer prognosis to identify patients at risk for progression and for diagnosis to improve the predictive capability of existing biomarkers.

1 April 2018 in Cell Reports
Verified
Journal Article
Open access
ANAdam Naguib
Adam Naguib
GMGrinu Mathew
Grinu Mathew
CRColleen R. Reczek
Colleen R. Reczek
KWKaitlin Watrud
Kaitlin Watrud
AAAlexandra Ambrico
Alexandra Ambrico
LTLloyd C Trotman
Lloyd C Trotman
A hallmark of advanced prostate cancer (PC) is the concomitant loss of PTEN and p53 function. To selectively eliminate such cells, we screened cytotoxic compounds on Pten-/-;Trp53-/- fibroblasts and their Pten-WT reference. Highly selective killing of Pten-null cells can be achieved by deguelin, a natural insecticide. Deguelin eliminates Pten-deficient cells through inhibition of mitochondrial complex I (CI). Five hundred-fold higher drug doses are needed to obtain the same killing of Pten-WT cells, even though deguelin blocks their electron transport chain equally well. Selectivity arises because mitochondria of Pten-null cells consume ATP through complex V, instead of producing it. The resulting glucose dependency can be exploited to selectively kill Pten-null cells with clinically relevant CI inhibitors, especially if they are lipophilic. In vivo, deguelin suppressed disease in our genetically engineered mouse model for metastatic PC. Our data thus introduce a vulnerability for highly selective targeting of incurable PC with inhibitors of CI.

13 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ICIrene Casanova-Salas
Irene Casanova-Salas
EMEsther Masiá
Esther Masiá
AAAna Armiñán
Ana Armiñán
ACAna Calatrava
Ana Calatrava
Caterina MancarellaCaterina Mancarella
Caterina Mancarella
JOSE ANTONIO LOPEZ-GUERREROJOSE ANTONIO LOPEZ-GUERRERO
JOSE ANTONIO LOPEZ-GUERRERO
MiRNAs are predicted to control the activity of approximately 60% of all protein-coding genes participating in the regulation of several cellular processes and diseases, including cancer. Recently, we have demonstrated that miR-187 is significantly downregulated in prostate cancer (PCa) and here we propose a proteomic approach to identify its potential targets. For this purpose, PC-3 cells were transiently transfected with miR-187 precursor and miRNA mimic negative control. Proteins were analyzed by a two-dimensional difference gel electrophoresis (2D-DIGE) and defined as differentially regulated if the observed fold change was ±1.06. Then, MALDI-TOF MS analysis was performed after protein digestion and low abundance proteins were identified by LC–MS/MS. Peptides were identified by searching against the Expasy SWISS PROT database, and target validation was performed both in vitro by western blot and qRT-PCR and in clinical samples by qRT-PCR, immunohistochemistry and ELISA. DIGE analysis showed 9 differentially expressed spots (p<0.05) and 7 showed a down-regulated expression upon miR-187 re-introduction. Among these targets we identified aldehyde dehydrogenase 1A3 (ALDH1A3). ALDH1A3 expression was significantly downregulated in PC3, LNCaP and DU-145 cells after miR-187 re-introduction. Supporting these data, the expression of ALDH1A3 was found significantly (p<0.0001) up-regulated in PCa samples and inversely correlated (p<0.0001) with miR-187 expression, its expression being directly associated with Gleason score (p = 0.05). The expression of ALDH1A3 was measured in urine samples to evaluate the predictive capability of this biomarker for the presence of PCa and, at a signification level of 10%, PSA and also ALDH1A3 were significantly associated with a positive biopsy of PCa. In conclusion, our data illustrate for the first time the role of ALDH1A3 as a miR-187 target in PCa and provide insights in the utility of using this protein as a new biomarker for PCa.

1 November 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
MGMaría García-Flores
María García-Flores
ICIrene Casanova-Salas
Irene Casanova-Salas
JRJosé Rubio-Briones
José Rubio-Briones
ACAna Calatrava
Ana Calatrava
JDJosé Domínguez-Escrig
José Domínguez-Escrig
JOSE ANTONIO LOPEZ-GUERREROJOSE ANTONIO LOPEZ-GUERRERO
JOSE ANTONIO LOPEZ-GUERRERO

24 July 2012 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
ICIrene Casanova-Salas
Irene Casanova-Salas
JRJosé Rubio-Briones
José Rubio-Briones
AFAntonio Fernández-Serra
Antonio Fernández-Serra
JOSE ANTONIO LOPEZ-GUERREROJOSE ANTONIO LOPEZ-GUERRERO
JOSE ANTONIO LOPEZ-GUERRERO
Current prostate cancer (PCa) diagnosis is based in the serum prostate-specific antigen biomarker and digital rectal examination. However, these methods are limited by a low predictive value (24–37 %) and a high risk of mistaken results. During last years, new promising biomarkers such as Prostate Cancer Antigen 3 (PCA-3) and TMPRSS2-ETS fusion genes have been evaluated for their clinical use. However, the search of new biomarkers that could be used for PCa diagnosis and prognosis is still needed. Recent studies have demonstrated that the aberrant expression of microRNAs (miRNAs), small non-coding RNAs that negatively regulate gene expression, is related with the development of several cancers, including PCa. Since miRNAs serve as phenotypic signatures of different cancers, they appear as potential diagnostic, prognostic and therapeutic tools. Here, we review the current knowledge of miRNA expression patterns in PCa and their role in PCa prognosis and therapeutics.

27 March 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
Caterina MancarellaCaterina Mancarella
Caterina Mancarella
ICIrene Casanova-Salas
Irene Casanova-Salas
ACAna Calatrava
Ana Calatrava
SVSelena Ventura
Selena Ventura
CGCecilia Garofalo
Cecilia Garofalo
Katia ScotlandiKatia Scotlandi
Katia Scotlandi
ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents